Skip to content

Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders

Developing Optimal Parameters for Hyperpolarized Noble Gas (3He and 129Xe) and Inert Fluorinated Gas Magnetic Resonance Imaging of Lung Disorders

Status
Terminated
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02748798
Enrollment
10
Registered
2016-04-22
Start date
2020-11-10
Completion date
2021-10-16
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asbestosis, Asthma, Bronchiectasis, Chronic Obstructive Pulmonary Disease, Cold Virus, Cystic Fibrosis, Emphysema, Interstitial Lung Disease, Lung Cancer, Lung Infection, Lung Resection, Lung Transplant, Mesothelioma, Obstructive Sleep Apnea, Pulmonary Dysplasia, Pulmonary Embolism, Pulmonary Fibrosis, Pulmonary Hypertension, Seasonal Allergies

Brief summary

The goal of this research is to optimize the MRI system to obtain ideal lung images using Hyperpolarized (HP) Noble and Inert Fluorinated Gases as contrast agents. Lung coils tuned to the frequencies of these gases will be used. This study will take place at TBRHSC in the Cardiorespiratory Department and in the Research MRI facility.

Detailed description

MR images of the lung obtained using HP 3He, HP 129Xe, and inert fluorinated gases essentially show the distribution of the inhaled gas inside the lungs. Measurements can be performed on these images to provide additional information that can be related to pulmonary function. Participation will involve at least two study visits. During the first visit, participants will provide written, informed consent, and undergo eligibility screening. Study drug administration, use of the investigational devices, and MR imaging for this study will be performed at the 3T Research MRI at the Thunder Bay Regional Health Sciences Centre (TBRHSC). Pulmonary Function Tests (PFTs) will be performed at TBRHSC by a Registered Respiratory Therapist (RRT) and an MR Tech will be present for the duration of participant scans. Participants will be placed in the MRI with the appropriate chest coil wrapped around them like a vest. Several inhalation procedures will be carried out during scanning. Participants safety will be closely monitored throughout the entire study.

Interventions

DRUGHP 3He

3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.

DRUGHP 129Xe

129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.

DRUGPFP

Perfluoropropane (PFP) will be premixed and delivered to the participants with no further processing.

DRUGSF6

Sulfur hexafluoride (SF6) will be premixed and delivered to the participant with no further processing.

DEVICE129Xe Small and Large Human Lung Coil

The investigational 129Xe small and large quadrature lung coils are sensitive to 129Xe resonant frequencies and therefore will be paired with the investigational drug 129Xe. The size of the coil used will depend on the participants' body size.

DEVICE3He Human Lung Coil

The investigational 3He quadrature lung coil is sensitive to 3He resonant frequencies and therefore will be paired with the investigational drug 3He.

DEVICEPFP and SF6 Human Lung Coil

The investigational PFP and SF6 quadrature lung coil is sensitive to inert fluorinated gas resonant frequencies and therefore will be paired with both PFP and SF6.

Sponsors

Thunder Bay Regional Health Sciences Centre
CollaboratorOTHER
St. Joseph's Care Group
CollaboratorOTHER
Lakehead University
CollaboratorOTHER
Thunder Bay Regional Health Research Institute
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Is either: 1. A healthy volunteer (i.e.: someone not diagnosed with a lung disorder written below; this may include smokers who have not been diagnosed with a lung disorder) or 2. Has been diagnosed with one of the following respiratory disorders: lung transplants, lung resection, lung cancer, asthma, cystic fibrosis, chronic obstructive pulmonary disease, emphysema, mesothelioma, asbestosis, pulmonary embolism, interstitial lung disease, pulmonary fibrosis, bronchiectasis, seasonal allergies, pneumonia, cold virus, lung infection, pulmonary hypertension, pulmonary dysplasia, obstructive sleep apnea * Able to provide informed consent * Able to hold their breath for imaging: 1. Healthy volunteers enrolled in this study must be able to hold their breath for 25 seconds 2. Lung disorder participants must be able to hold their breath for 15 seconds

Exclusion criteria

* Have contraindication to MR imaging (i.e. ferrous implants, cardiac pacemakers) - determined by MR screening prior to scans. * Have a history of claustrophobia. * Female exclusion only: are or may be pregnant. * Requires an oxygen mask and cannot use a nasal cannula. * Blood oxygen saturation is below 92% (measured at rest in a sitting position, and with an O2 nasal cannula if the participant normally uses one). * Has had an acute respiratory infection in the past 10 days. * Is a student currently enrolled in a course at Lakehead University where the Principal Investigator (PI) is the instructor. * Is a student currently enrolled in a degree program at Lakehead University where the PI is their direct thesis supervisor. * Is currently an employee of the PI at the Thunder Bay Regional Research Institute (TBRRI) and/or Lakehead University.

Design outcomes

Primary

MeasureTime frameDescription
Signal to Noise Ratio2 yearsThe primary objective of this study is to determine an optimized set of scan parameters that will produce clear, anatomically and clinically relevant images of the lungs for healthy participants and various types of lung disorder participants, and using one or more gas type (3He, 129Xe, PFP, SF6).

Secondary

MeasureTime frameDescription
Correlation with PFTs2 yearsThe secondary objective of this study is to correlate the results with PFTs, including spirometry and plethysmography.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026